Optimer Pharmaceuticals



		Subscribe to RSS feed 2010 \| 2009 \| 2008 \| 2007 \| 2006 \| 2005 \| 2004 \| 2002 \| 2001 \| (9.2.2010) SAN DIEGO, CA Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting (9.1.2010) SAN DIEGO, CA Optimer Pharmaceuticals to Present at September 2010 Investor Conferences (8.19.2010) SAN DIEGO, CA Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency (8.5.2010) Waltham, MA In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1 (8.4.2010) SAN DIEGO, CA Optimer Pharmaceuticals Reports Second Quarter 2010 Financial Results (7.29.2010) SAN DIEGO, CA Optimer Pharmaceuticals Submits Fidaxomicin Marketing Authorization Application for the Treatment of Clostridium difficile Infection (7.28.2010) SAN DIEGO, CA Optimer Pharmaceuticals to Present at August 2010 Investor Conferences (7.8.2010) SAN DIEGO, CA Optimer Pharmaceuticals Receives Milestone Payment from Cempra for Next-Generation Macrolide Antibiotic (6.1.2010) SAN DIEGO, CA Optimer Pharmaceuticals to Present at June 2010 Investor Conferences (5.24.2010) SAN DIEGO, CA Optimer Pharmaceuticals and Biocon Limited Announce Manufacturing and Supply Agreement for Fidaxomicin (5.6.2010) SAN DIEGO, CA Optimer Pharmaceuticals Appoints Pedro Lichtinger as President and CEO to Succeed Michael N. Chang, Ph.D., Who Will Serve as Chairman of the Board (5.6.2010) SAN DIEGO, CA Optimer Pharmaceuticals Reports First Quarter 2010 Financial Results (5.4.2010) SAN DIEGO, CA Data from Optimers Second Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Featured in Oral Presentation at Digestive Disease Week (4.22.2010) SAN DIEGO, CA Optimer Pharmaceuticals Announces Oral Presentation at Digestive Disease Week (DDW) Featuring Data from the Second Fidaxomicin Phase 3 Trial (4.10.2010) SAN DIEGO, CA Positive Results from Optimer Pharmaceuticals Second Phase 3 Study of Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) Presented at ECCMID (4.6.2010) SAN DIEGO Optimer Pharmaceuticals Announces Presentations of Data from the Fidaxomicin Phase 3 Trials at ECCMID (3.11.2010) SAN DIEGO, CA Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Financial Results (3.3.2010) SAN DIEGO, CA Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2009 Financial Results (3.1.2010) SAN DIEGO, CA Optimer Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference (3.1.2010) SAN DIEGO, CA Optimer Pharmaceuticals, Inc. Announces Completion of Public Offering of Common Stock (2.24.2010) SAN DIEGO, CA Optimer Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock (2.4.2010) SAN DIEGO, CA Optimer Pharmaceuticals Announces Positive Results from Second Fidaxomicin Phase 3 Study in Patients with Clostridium Difficile Infection

(4.22.2010) SAN DIEGO, CA

Optimer Pharmaceuticals Announces Oral Presentation at Digestive Disease Week (DDW) Featuring Data from the Second Fidaxomicin Phase 3 Trial

SAN DIEGO, CA - April 22, 2010 – Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced that data from the second fidaxomicin Phase 3 clinical study will be presented in an oral presentation at Digestive Disease Week (DDW) 2010 in New Orleans.

“Randomized Clinical Trial (RCT) in Clostridium difficile Infection (CDI) Confirms Superiority of Fidaxomicin over Vancomycin”

Oral Presentation by:Stuart Johnson, M.D.

Tuesday, May 4, 2010 2:15pm-3:45pm Central Daylight Time

Abstract number: 828630

Location: Ballroom C, Ernest N. Morial Convention Center

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infectives to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection. Optmer has reported positive top-line results from two Phase 3 trials of fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Optimer has also successfully completed two Phase 3 trials with Pruvel. Additional information can be found at http://www.optimerpharma.com.

Contacts

Optimer Pharmaceuticals, Inc.

Christina Donaghy, Corporate Communications Manager

John D. Prunty, Chief Financial Officer & VP Finance

858-909-0736

Porter Novelli Life Sciences

Jason I. Spark, Vice President

619-849-6005